Literature DB >> 2093839

Fluconazole in the treatment of oropharyngeal candidosis in HIV-positive patients.

G Just-Nübling1, G Gentschew, M Döhle, C Böttinger, E B Helm, W Stille.   

Abstract

106 HIV-positive patients with 129 episodes of oropharyngeal Candida infection were treated with fluconazole (50-300 mg/d). Treatment lasted from 4 to 23 days. The majority of patients were in more advanced stages of HIV infection (82% AIDS cases). Therapy with fluconazole led to complete healing or improvement of clinical symptoms in 93% of all treatment courses. However, according to cultural findings, an elimination or recession of pathogens was achieved in only 70% of cases. Cultural monitoring showed a slow reduction of pathogens, as opposed to a fairly rapid clinical improvement. Candida albicans was the most frequently isolated Candida species (n = 128); the most selected Candida species during treatment were C. glabrata, C. krusei, and C. inconspicua. It is remarkable that C. glabrata, a low-grade pathogen, caused enanthema in 2 patients and a typical oral thrush in 1 patient. Fluconazole was well-tolerated, and apart from mild gastro-intestinal symptoms in 1 patient, no severe side effects were observed.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2093839     DOI: 10.1111/myc.1990.33.9-10.435

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  8 in total

1.  Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

Review 2.  Drug treatment of HIV-related opportunistic infections.

Authors:  M E Klepser; T B Klepser
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

4.  Differential and enrichment media for selective culture and recognition of yeast species from clinical material.

Authors:  B Louwagie; I Surmont; J Verhaegen; F Odds
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

5.  Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients.

Authors:  G Just-Nübling; G Gentschew; K Meissner; J Odewald; S Staszewski; E B Helm; W Stille
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

6.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

Review 7.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

8.  Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole.

Authors:  M Ruhnke; A Eigler; E Engelmann; B Geiseler; M Trautmann
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.